Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns ‌that ...

GSK Plc’s older respiratory medicines showed lackluster sales in the first quarter, leaving HIV and cancer drugs to drive ...

GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ...

GSK’s Tesaro unit took a blow in its legal feud with Jemperli developer AnaptysBio, with a Delaware court dismissing GSK’s ...

In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...

By Bhanvi Satija LONDON, April 29 (Reuters) - British drugmaker GSK reported first-quarter profit and sales above analysts' ...

The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compared with £2.53 billion for ...

While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to ...

Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the ...

Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP ...

LONDON, April 29 () - British drugmaker ‌GSK reported ‌first-quarter profit above ​analysts' expectations on Wednesday, ...